AJANTPHARMBSEAjanta Pharma LtdMediumNeutral
Announced Fri, 27 Mar · 17:27 IST

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on March 27, 2026 for Aayush Agrawal, trustee ....

Pledge ReleasedOwnership Changes View source PDF

AJANTPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+0.1%1-day move
₹2806.70
prior close
₹2787.40
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.7-0.9-0.5-0.2+0.1-1.4-1.7-3.4-3.6-0.1-0.5+0.8+4.8+22.0
Up moveDown movePending
AI summary

Aayush Agrawal, trustee of Aayush Agrawal Trust and promoter of Ajanta Pharma, has disclosed creation of pledge on 10,42,500 shares (about 0.83% of share capital) and release of pledge on 8,50,000 shares (about 0.68%). The new pledges were created on March 23, 2026 with Motilal Oswal Financial Services (8,50,000 shares, for a new loan) and Ashika Credit Capital (1,92,500 shares, for a new loan). The release of 8,50,000 pledged shares from Motilal Oswal on March 25, 2026 was because the loan was not taken. Net new encumbrance is about 1,92,500 shares.

Likely market impact

This is a routine encumbrance disclosure showing the promoter is partially unwinding old pledges while taking new ones for fresh borrowing. No change in promoter ownership — purely collateral reshuffling, so limited direct impact on stock price.